AI Engines For more Details: Perplexity Kagi Labs You
Glaucoma: Eserine hemisulfate salt is sometimes used in the treatment of glaucoma, a group of eye disorders characterized by increased intraocular pressure (IOP). It works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure. However, its use in glaucoma has diminished over time due to the availability of more effective and better-tolerated medications.
Myasthenia Gravis: Eserine hemisulfate salt has been used in the past for the symptomatic treatment of myasthenia gravis, a neuromuscular disorder characterized by muscle weakness and fatigue. It works by inhibiting the enzyme acetylcholinesterase, thereby increasing the concentration of acetylcholine at the neuromuscular junction and improving muscle strength. However, other medications such as pyridostigmine are more commonly used for this indication today due to their longer duration of action and fewer side effects.
Anticholinergic Toxicity: Eserine hemisulfate salt is sometimes employed as an antidote in the management of anticholinergic toxicity, which can occur due to overdose or adverse reactions to medications with anticholinergic properties. By inhibiting acetylcholinesterase, eserine increases the levels of acetylcholine, which can help counteract the effects of excessive anticholinergic activity, such as dry mouth, blurred vision, urinary retention, confusion, and tachycardia.
Alzheimer's Disease: Eserine hemisulfate salt has been investigated for its potential role in the treatment of Alzheimer's disease, a neurodegenerative disorder characterized by cognitive decline and memory impairment. By increasing acetylcholine levels in the brain, eserine may theoretically improve cognitive function in Alzheimer's patients. However, its use in Alzheimer's disease is not widespread, and other pharmacological approaches are more commonly employed for this condition.
Ophthalmic Procedures: Eserine hemisulfate salt may be used as a miotic agent in ophthalmic procedures to constrict the pupil and facilitate intraocular surgery, such as cataract extraction or lens implantation.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 1.1 | 0.3 | 2.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.9 | 0.4 | 1.25 |
| Allergies | 1.2 | 0.6 | 1 |
| Allergy to milk products | 0.4 | 0.6 | -0.5 |
| Alzheimer's disease | 1.1 | 2.4 | -1.18 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.1 | 9 |
| Ankylosing spondylitis | 1.9 | 0.6 | 2.17 |
| Anorexia Nervosa | 0.3 | 1.1 | -2.67 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 2 | 1.1 | 0.82 |
| Atherosclerosis | 0.4 | 0.5 | -0.25 |
| Atrial fibrillation | 1.2 | 0.9 | 0.33 |
| Autism | 2.6 | 3.1 | -0.19 |
| Autoimmune Disease | 0.9 | 0.5 | 0.8 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.6 | |
| Biofilm | 0.8 | 0.8 | |
| Bipolar Disorder | 0.6 | 1.1 | -0.83 |
| Brain Trauma | 0.3 | 0.5 | -0.67 |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.6 | 0.6 | |
| Carcinoma | 1.4 | 1.4 | |
| Celiac Disease | 0.7 | 0.6 | 0.17 |
| Cerebral Palsy | 0.6 | 0.5 | 0.2 |
| Chronic Fatigue Syndrome | 0.9 | 1 | -0.11 |
| Chronic Kidney Disease | 0.9 | 1.1 | -0.22 |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 2 | -0.33 |
| Chronic Urticaria (Hives) | 1.2 | 0.3 | 3 |
| Coagulation / Micro clot triggering bacteria | 1 | 0.8 | 0.25 |
| Cognitive Function | 0.3 | 0.8 | -1.67 |
| Colorectal Cancer | 2.2 | 0.6 | 2.67 |
| Constipation | 0.9 | 0.5 | 0.8 |
| Coronary artery disease | 1 | 1.1 | -0.1 |
| COVID-19 | 1.5 | 1.8 | -0.2 |
| Crohn's Disease | 2.6 | 1.5 | 0.73 |
| cystic fibrosis | 0.7 | 0.5 | 0.4 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 1.1 | 0.8 | 0.38 |
| Denture Wearers Oral Shifts | 0.8 | 0.8 | |
| Depression | 2.4 | 2.5 | -0.04 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.5 | 0.5 | 2 |
| Endometriosis | 1.2 | 1.5 | -0.25 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 1.2 | 1.2 | |
| erectile dysfunction | 0.9 | 0.9 | |
| Fibromyalgia | 0.5 | 0.5 | 0 |
| Functional constipation / chronic idiopathic constipation | 1.5 | 1.2 | 0.25 |
| gallstone disease (gsd) | 1 | 0.8 | 0.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 0.6 | 0.33 |
| Generalized anxiety disorder | 1.5 | 0.6 | 1.5 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.3 | 0.3 | 0 |
| Graves' disease | 0.3 | 1.4 | -3.67 |
| Gulf War Syndrome | 0.6 | 0.6 | |
| Halitosis | 1 | 0.3 | 2.33 |
| Hashimoto's thyroiditis | 1.1 | 0.3 | 2.67 |
| Heart Failure | 1.5 | 0.5 | 2 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.6 | 0.6 | |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | |
| hyperglycemia | 1 | 1 | |
| hypertension (High Blood Pressure | 1.2 | 1.3 | -0.08 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.7 | 0.7 | |
| IgA nephropathy (IgAN) | 0.6 | 1.3 | -1.17 |
| Inflammatory Bowel Disease | 2 | 2.4 | -0.2 |
| Insomnia | 1.1 | 1.4 | -0.27 |
| Intelligence | 0.4 | 0.3 | 0.33 |
| Intracranial aneurysms | 0.3 | 0.3 | 0 |
| Irritable Bowel Syndrome | 2.1 | 1.7 | 0.24 |
| ischemic stroke | 0.7 | 1.1 | -0.57 |
| Liver Cirrhosis | 2.7 | 1.8 | 0.5 |
| Long COVID | 1.9 | 1.5 | 0.27 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.6 | 0.6 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.1 | 0.3 | 2.67 |
| ME/CFS with IBS | 0.3 | 0.1 | 2 |
| ME/CFS without IBS | 0.3 | 0.3 | |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 2.1 | 1.8 | 0.17 |
| Mood Disorders | 2.4 | 2.4 | 0 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.8 | |
| Multiple Sclerosis | 1.4 | 1.5 | -0.07 |
| Multiple system atrophy (MSA) | 0.1 | 0.1 | |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 0.9 | -0.9 | |
| Neuropathy (all types) | 0.3 | 1.1 | -2.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.4 | 1.1 | 1.18 |
| Obesity | 2.8 | 2.1 | 0.33 |
| obsessive-compulsive disorder | 1.5 | 0.9 | 0.67 |
| Osteoarthritis | 0.9 | 0.3 | 2 |
| Osteoporosis | 1.4 | 0.3 | 3.67 |
| pancreatic cancer | 0.5 | 0.3 | 0.67 |
| Parkinson's Disease | 2 | 2.9 | -0.45 |
| Polycystic ovary syndrome | 2 | 0.8 | 1.5 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| primary biliary cholangitis | 0.6 | 0.6 | 0 |
| Primary sclerosing cholangitis | 0.9 | 0.3 | 2 |
| Psoriasis | 0.7 | 1.2 | -0.71 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.5 | 1.4 | 0.79 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 1.5 | 1.4 | 0.07 |
| scoliosis | 0.4 | 0.1 | 3 |
| Sjögren syndrome | 1.6 | 1.6 | |
| Sleep Apnea | 0.9 | 0.8 | 0.13 |
| Slow gastric motility / Gastroparesis | 0.4 | 0.4 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 1.2 | |
| Stress / posttraumatic stress disorder | 0.9 | 0.8 | 0.13 |
| Systemic Lupus Erythematosus | 1.7 | 0.8 | 1.13 |
| Tic Disorder | 0.3 | 0.3 | 0 |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 1.5 | 1.1 | 0.36 |
| Type 2 Diabetes | 2.1 | 1.8 | 0.17 |
| Ulcerative colitis | 1.7 | 1.2 | 0.42 |
| Unhealthy Ageing | 1.3 | 0.8 | 0.63 |
| Vitiligo | 0.6 | 0.1 | 5 |
